Building Evidence: Effective Palliative/End of Life Care Interventions (R01 Clinical Trial Optional) | PAR 18 173

Opportunity Information: Apply for PAR 18 173

Building Evidence: Effective Palliative/End of Life Care Interventions (R01 Clinical Trial Optional) (PAR 18-173) is a National Institutes of Health (NIH) discretionary grant opportunity designed to strengthen the research base for end-of-life and palliative care (EOLPC). The core purpose is to support rigorous studies that develop and test palliative and end-of-life care interventions or models of care, with a strong emphasis on outcomes that matter to patients and families. In practical terms, NIH is looking for projects that can show, with solid evidence, what approaches work best for people living with serious, advanced illness and for the relatives or caregivers supporting them.

A central priority of the announcement is testing interventions that reflect racial, ethnic, and cultural diversity across both pediatric and adult populations. The FOA highlights an urgent need for studies that are responsive to the realities of diverse communities, including how culture, language, beliefs, and structural factors shape serious-illness experiences and care preferences. Projects are expected to focus on individual- and family-centered outcomes rather than purely clinical or utilization outcomes, meaning applicants should measure impacts such as symptom burden and relief, quality of life, emotional distress, communication and decision-making quality, caregiver strain, family satisfaction with care, goal-concordant care, and other outcomes that directly reflect what patients and families value during serious illness and near the end of life.

The mechanism is an R01 research project grant, and clinical trials are optional, which signals flexibility in study design while still emphasizing strong evaluation. The FOA explicitly calls for trials to test the efficacy and effectiveness of interventions and/or care models. That typically implies the agency is interested both in controlled testing to determine whether an approach can work under more ideal conditions (efficacy) and in real-world testing to determine whether it does work in routine practice settings (effectiveness). Applicants would generally be expected to propose well-justified methods, appropriate comparison conditions, meaningful outcomes, and a design that matches the research question, whether the intervention is delivered in hospitals, outpatient clinics, home-based care, nursing facilities, hospice settings, or community-based programs.

Eligibility is broad and intentionally inclusive, reflecting NIH interest in drawing proposals from many kinds of institutions and communities. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled colleges and universities; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized governments; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education when specified in the listing); for-profit organizations other than small businesses; small businesses; and other organizations. The announcement also names additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, tribal governments other than federally recognized, non-U.S. entities (foreign organizations), and U.S. territories or possessions. This breadth suggests the program is open to partnerships that combine clinical expertise, community trust, cultural knowledge, and implementation capacity.

Administratively, the opportunity is listed under CFDA number 93.361 and is categorized under Education and Health. The original closing date shown in the source data is June 10, 2019, with a creation date of November 30, 2017. While an award ceiling and expected number of awards are not specified in the provided data, the overall message is that NIH wants well-designed, outcomes-focused research that can directly inform practice and improve the quality and equity of palliative and end-of-life care for diverse children and adults with serious, advanced illness.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Building Evidence: Effective Palliative/End of Life Care Interventions (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361.
• This funding opportunity was created on 2017-11-30.
• Applicants must submit their applications by 2019-06-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 18 173

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: